Downregulating the expression of circular ANRIL is a new phenomenon in diagnosis and treatment of CAD because inhibition of this molecule reduces vascular endothelial injury, oxidative stress, and inflammatory responses [83]. This evidence concerns the gene CDKN2B-AS1 and coronary artery disorder.